AusBiotech signs MOU with KoreaBIO

8 November 2013

The AusBiotech 2013 national conference culminated last week in the signing of a memorandum of understanding (MOU) between the respective trade groups AusBiotech and the Korea Biotechnology Industry Organization (KoreaBIO).

The MOU is to recognize the key role that biotechnology plays in economic and social development, and the benefits of a strategic partnership between Australia and South Korea. AusBiotech and KoreaBIO are the industry associations representing the biotechnology industries of Australia and South Korea respectively. Signed by Eun-Hee Bae, president of the KoreBIO, Anna Lavelle, AusBiotech’s chief executive, the MOU is to promote collaboration and cooperation in the area of biotechnology.

Objectives of the alliance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >